Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNB2 | O95067 | 14/20 | 1.00 |
| ▸ | CDK1 | P06493 | 14/20 | 1.00 |
| ▸ | CCNB1 | P14635 | 14/20 | 1.00 |
| ▸ | CCNB3 | Q8WWL7 | 14/20 | 1.00 |
| ▸ | RET | P07949 | 12/20 | 1.00 |
| ▸ | CDC7 | O00311 | 1/20 | 0.60 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.60 |
| ▸ | PIM1 | P11309 | 1/20 | 0.60 |
| ▸ | PRKACA | P17612 | 1/20 | 0.60 |
| ▸ | GSK3B | P49841 | 1/20 | 0.60 |
| ▸ | HIPK2 | Q9H2X6 | 1/20 | 0.60 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.60 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.60 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3767756 | 0.91 | CCNB2 (0.83) | CCNB2CDK1CCNB1CCNB3RET | |
| SCHEMBL3764784 | 0.87 | RET (0.80) | CCNB2CDK1CCNB1CCNB3RET | |
| SCHEMBL3767765 | 0.87 | RET (0.77) | CCNB2CDK1CCNB1CCNB3RET | |
| SCHEMBL3779801 | 0.86 | CCNB2 (1.00) | CCNB2CDK1CCNB1CCNB3RET | |
| SCHEMBL3779637 | 0.86 | CCNB2 (1.00) | CCNB2CDK1CCNB1CCNB3RET | |
| SCHEMBL3769927 | 0.86 | CCNB2 (1.00) | CCNB2CDK1CCNB1CCNB3RET | |
| SCHEMBL3775338 | 0.86 | CCNB2 (1.00) | CCNB2CDK1CCNB1CCNB3RET | |
| SCHEMBL3769910 | 0.85 | RET (0.77) | CCNB2CDK1CCNB1CCNB3RET | |
| SCHEMBL3769243 | 0.85 | RET (0.77) | CCNB2CDK1CCNB1CCNB3RET | |
| SCHEMBL13357503 | 0.85 | RET (0.84) | CCNB2CDK1CCNB1CCNB3RET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7855205-B2 | Pyrimidinyl substituted fused-pyrrolyl compounds useful in treating kinase disorders | JANSSEN PHARMACEUTICA NV (BE) | 2010-12-21 | — | — | US | disclosed |
| US-7855205-B2 | Pyrimidinyl substituted fused-pyrrolyl compounds useful in treating kinase disorders | JANSSEN PHARMACEUTICA NV (BE) | 2010-12-21 | — | — | US | disclosed |
| US-7855205-B2 | Pyrimidinyl substituted fused-pyrrolyl compounds useful in treating kinase disorders | JANSSEN PHARMACEUTICA NV (BE) | 2010-12-21 | — | — | US | disclosed |
| US-20060183900-A1 | Pyrimidinyl substituted fused-pyrrolyl compounds useful in treating kinase disorders | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-08-17 | — | — | US | disclosed |
| WO-2006050076-A1 | PYRIMIDINYL SUBSTITUTED FUSED-PYRROLYL COMPOUNDS USEFUL IN TREATING KINASE DISORDERS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-05-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060183900-A1 | Pyrimidinyl substituted fused-pyrrolyl compounds useful in treating kinase disorders | TK1, MAP3K1, MAP3K2 | CCNB2 358/4885CDK1 71/4885CCNB1 441/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.